









Mercado
/
Acciones
/
nasdaq-amgn
/

Amgen Inc

AMGN

274.710USD

+1.625+0.60%

Cierre 09/17, 16:00（ET）Cotizaciones retrasadas 15 min

147.88BCap. mercado

22.34P/E TTM



Amgen Inc

274.710

+1.625+0.60%

Descripción general Compañía Finanzas Análisis

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Información de la empresa

Símbolo de cotizaciónAMGN

Nombre de la empresaAmgen Inc

Fecha de salida a bolsaJun 17, 1983

Director ejecutivoMr. Robert A. (Bob) Bradway

Número de empleados28000

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 17

DirecciónOne Amgen Center Drive

CiudadTHOUSAND OAKS

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal91320-1799

Teléfono18054471000

Sitio Webhttps://www.amgen.com/

Símbolo de cotizaciónAMGN

Fecha de salida a bolsaJun 17, 1983

Director ejecutivoMr. Robert A. (Bob) Bradway

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+1.52%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+3.06%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

41.70K

+6.10%

Dr. Tyler Jacks

Independent Director

17.19K

+4.94%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+6.57%

Ms. Rachna Khosla

Senior Vice President - Business Development

7.78K

-16.17%

Dr. Brian J. Druker, M.D.

Independent Director

7.57K

+11.97%

Dr. Wanda M. Austin, Ph.D.

Independent Director

7.35K

+12.36%

Ms. Nancy A. Grygiel

Senior Vice President, Chief Compliance Officer

6.04K

-17.35%

Ms. Amy E. Miles

Independent Director

4.84K

+20.06%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+1.52%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+3.06%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

41.70K

+6.10%

Dr. Tyler Jacks

Independent Director

17.19K

+4.94%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+6.57%

Ms. Rachna Khosla

Senior Vice President - Business Development

7.78K

-16.17%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Other products

1.65B

20.21%

Prolia

1.10B

13.49%

Repatha

656.00M

8.05%

XGEVA

566.00M

6.95%

Enbrel

510.00M

6.26%

Otro

3.67B

45.05%

Por regiónUSD

Nombre

Ganancia

Proporción

5.34B

65.55%

ROW

2.09B

25.64%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Other products

1.65B

20.21%

Prolia

1.10B

13.49%

Repatha

656.00M

8.05%

XGEVA

566.00M

6.95%

Enbrel

510.00M

6.26%

Otro

3.67B

45.05%

Estadísticas de accionistas

Actualizado: mar., 19 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

10.00%

State Street Global Advisors (US)

5.45%

BlackRock Institutional Trust Company, N.A.

5.36%

Capital International Investors

3.51%

Capital World Investors

3.13%

Otro

72.54%

Accionistas

Proporción

The Vanguard Group, Inc.

10.00%

State Street Global Advisors (US)

5.45%

BlackRock Institutional Trust Company, N.A.

5.36%

Capital International Investors

3.51%

Capital World Investors

3.13%

Otro

72.54%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

53.27%

Investment Advisor/Hedge Fund

19.45%

Research Firm

4.96%

Pension Fund

2.21%

Bank and Trust

1.96%

Sovereign Wealth Fund

1.18%

Insurance Company

0.61%

Hedge Fund

0.50%

Individual Investor

0.17%

Otro

15.69%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

4453

451.65M

83.89%

+6.94M

2025Q1

4519

453.49M

84.33%

+5.91M

2024Q4

4466

443.40M

82.54%

+89.78K

2024Q3

4316

438.01M

81.42%

-5.13M

2024Q2

4284

437.79M

81.61%

-4.94M

2024Q1

4192

436.25M

81.40%

-5.11M

2023Q4

4150

435.28M

81.36%

+42.25K

2023Q3

3990

429.94M

80.36%

-4.48M

2023Q2

3936

426.14M

79.65%

-4.34M

2023Q1

3951

427.29M

80.00%

-4.36M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

52.63M

9.79%

+145.69K

+0.28%

Mar 31, 2025

State Street Global Advisors (US)

29.18M

5.43%

-254.42K

-0.86%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

28.50M

5.3%

-289.51K

-1.01%

Mar 31, 2025

Capital International Investors

15.13M

2.81%

+2.92M

+23.93%

Mar 31, 2025

Capital World Investors

16.70M

3.11%

+10.21M

+157.12%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.73M

2.37%

+252.31K

+2.02%

Mar 31, 2025

Charles Schwab Investment Management, Inc.

12.21M

2.27%

-999.66K

-7.57%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

11.11M

2.07%

-33.38K

-0.30%

Jun 30, 2025

PRIMECAP Management Company

12.39M

2.3%

-613.83K

-4.72%

Mar 31, 2025

Morgan Stanley Smith Barney LLC

8.73M

1.62%

+352.70K

+4.21%

Mar 31, 2025

ETFs relacionados

Actualizado: mar., 2 de sep

Nombre

Proporción

VanEck Biotech ETF

16.29%

FT Vest DJIA Dogs 10 Target Income ETF

10.17%

ProShares Ultra Nasdaq Biotechnology

7.79%

Amplify Weight Loss Drug & Treatment ETF

7.17%

Invesco Nasdaq Biotechnology ETF

6.93%

iShares Biotechnology ETF

6.85%

Invesco Biotechnology & Genome ETF

5.28%

Invesco Pharmaceuticals ETF

5.16%

Invesco Dow Jones Industrial Average Dividend ETF

5.11%

Invesco QQQ Low Volatility ETF

4.51%

VanEck Biotech ETF

Proporción16.29%

FT Vest DJIA Dogs 10 Target Income ETF

Proporción10.17%

ProShares Ultra Nasdaq Biotechnology

Proporción7.79%

Amplify Weight Loss Drug & Treatment ETF

Proporción7.17%

Invesco Nasdaq Biotechnology ETF

Proporción6.93%

iShares Biotechnology ETF

Proporción6.85%

Invesco Biotechnology & Genome ETF

Proporción5.28%

Invesco Pharmaceuticals ETF

Proporción5.16%

Invesco Dow Jones Industrial Average Dividend ETF

Proporción5.11%

Invesco QQQ Low Volatility ETF

Proporción4.51%

Dividendos

Un total de 21.35B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Dec 10, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 07, 2025

Feb 14, 2025

Oct 25, 2024

AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024

Nov 18, 2024

Dec 09, 2024

Nov 18, 2024

Aug 02, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 06, 2024

Aug 16, 2024

Mar 06, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024

May 17, 2024

Jun 07, 2024

May 16, 2024

Dec 12, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024

Feb 16, 2024

Mar 07, 2024

Feb 15, 2024

Oct 24, 2023

AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023

Nov 17, 2023

Dec 08, 2023

Nov 16, 2023

Aug 01, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Sep 08, 2023

Aug 17, 2023

Mar 07, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023

May 18, 2023

Jun 08, 2023

May 17, 2023

Dec 12, 2022

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023

Feb 15, 2023

Mar 08, 2023

Feb 14, 2023

Oct 28, 2022

AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022

Nov 17, 2022

Dec 08, 2022

Nov 16, 2022

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

